← Back to Screener
Silexion Therapeutics Corp Ordinary Shares (SLXN)
Price$4.67
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-91.42%
Price vs S&P 500 (4W)-11.04%
VGM Score15.02
Market Capitalization$1.96M
All Metrics
Book Value / Share (Quarterly)$0.93
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-38.43
Price vs S&P 500 (YTD)-83.83%
EPS (TTM)$-55.60
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-55.60
EPS (Annual)$-89.60
ROI (Annual)-285.59%
Cash / Share (Quarterly)$7.72
ROA (Last FY)-165.10%
EBITD / Share (TTM)$-38.24
Cash Flow / Share (Annual)$-34.63
P/B Ratio6.72x
P/B Ratio (Quarterly)14.65x
Net Income / Employee (Annual)$-916,300
Net Interest Coverage (TTM)-44.11x
ROA (TTM)-176.68%
EPS Incl Extra (Annual)$-89.60
Current Ratio (Annual)2.41x
Quick Ratio (Quarterly)0.62x
3-Month Avg Trading Volume0.40M
52-Week Price Return-96.62%
Revenue / Employee (TTM)$0
52-Week High$223.60
EPS Excl Extra (Annual)$-89.60
26-Week Price Return-83.50%
Quick Ratio (Annual)2.20x
13-Week Price Return-71.70%
Total Debt / Equity (Annual)0.60x
Current Ratio (Quarterly)1.00x
Enterprise Value$1.10M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$19.16
3-Month Return Std Dev234.34%
Net Income / Employee (TTM)$-993,100
ROE (Last FY)-457.63%
EPS Basic Excl Extra (Annual)$-89.60
Total Debt / Equity (Quarterly)5.34x
EPS Incl Extra (TTM)$-55.60
ROI (TTM)-289.43%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-120.99%
Year-to-Date Return-75.68%
5-Day Price Return-6.22%
EPS Normalized (Annual)$-89.60
ROA (5Y Avg)-167.88%
Month-to-Date Return-4.88%
EBITD / Share (Annual)$-87.39
LT Debt / Equity (Annual)0.60x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-55.60
P/B Ratio (Annual)2.31x
Book Value / Share (Annual)$8.33
Price vs S&P 500 (13W)-79.95%
Beta-0.33x
P/FCF (Annual)2.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-516.87%
52-Week Low$2.31
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-8.50est. -13.16
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLXNSilexion Therapeutics Corp Ordinary Shares | — | — | F | $4.67 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Silexion Therapeutics is a clinical-stage biotechnology company developing targeted treatments for KRAS-driven cancers. Its lead product candidate, SIL204, is a locally administered siRNA designed to treat locally advanced pancreatic cancer in combination with standard chemotherapy, specifically targeting tumors with KRAS G12D and G12V mutations. The company focuses on non-resectable cases where surgical removal is not possible.